We exhibit that these inhibitors suppress SLC15A4-mediated endolysosomal TLR and NOD capabilities in a number of human and mouse immune cells; we offer evidence of their capacity to suppress inflammation in vivo and in medical settings; and we offer insights into their system of action. Our findings create SLC15A4 for a druggable concentrate on wit